Gotham Asset Management LLC Buys 13,986 Shares of IDEXX Laboratories, Inc. $IDXX

Gotham Asset Management LLC lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 40.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,643 shares of the company’s stock after buying an additional 13,986 shares during the quarter. Gotham Asset Management LLC’s holdings in IDEXX Laboratories were worth $31,078,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of IDXX. Fred Alger Management LLC grew its stake in IDEXX Laboratories by 60.8% during the third quarter. Fred Alger Management LLC now owns 27,075 shares of the company’s stock valued at $17,298,000 after acquiring an additional 10,236 shares in the last quarter. Focus Partners Wealth lifted its stake in IDEXX Laboratories by 1.4% in the 3rd quarter. Focus Partners Wealth now owns 51,918 shares of the company’s stock worth $33,170,000 after purchasing an additional 724 shares in the last quarter. EFG Asset Management Americas Corp. boosted its holdings in IDEXX Laboratories by 3.3% in the 3rd quarter. EFG Asset Management Americas Corp. now owns 5,775 shares of the company’s stock valued at $3,690,000 after purchasing an additional 183 shares during the period. Element Capital Management LLC bought a new position in IDEXX Laboratories in the 3rd quarter valued at $507,000. Finally, Elevation Point Wealth Partners LLC grew its position in shares of IDEXX Laboratories by 682.1% during the 3rd quarter. Elevation Point Wealth Partners LLC now owns 524 shares of the company’s stock valued at $335,000 after purchasing an additional 457 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on IDXX shares. Piper Sandler decreased their price target on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 28th. BTIG Research reduced their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. UBS Group decreased their target price on IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 3rd. Finally, Barclays dropped their price target on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $783.33.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $586.37 on Tuesday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $769.98. The company has a fifty day moving average of $656.25 and a 200-day moving average of $666.45. The company has a market capitalization of $46.69 billion, a P/E ratio of 44.86, a P/E/G ratio of 3.48 and a beta of 1.66. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the company earned $2.53 EPS. The firm’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 2,693 shares of the stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $661.54, for a total transaction of $1,781,527.22. Following the transaction, the executive vice president directly owned 19,899 shares in the company, valued at approximately $13,163,984.46. This represents a 11.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael G. Erickson sold 5,371 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total value of $3,369,657.98. Following the transaction, the executive vice president directly owned 12,693 shares in the company, valued at approximately $7,963,334.34. This represents a 29.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 45,957 shares of company stock worth $29,862,109. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.